New RNA-based active agents reliably protect plants against the Cucumber mosaic virus (CMV), the most common virus in ...

RNAi -- functions specifically to silence, or deactivate, genes. Among other applications, it promises to be groundbreaking ...

Gaining an understanding of RNA epigenetic modifications offers opportunities for identifying new biomarkers and drug targets that are associated with diseases such as cancer and neurological ...

The pathogen C. diff - the most common cause of health care-associated infectious diarrhea - can use a compound that kills ...

The pathogen C. diff—the most common cause of health care-associated infectious diarrhea—can use a compound that kills the ...

Fosun Pharma continues to uphold the internationalization strategy in multiple dimensions, such as innovative R&D, licensing, manufacturing and operations as well as commercialization. In 2024, ...

Amvuttra is an RNA interference drug that works to deliver ... Alnylam has estimated there are around 9,000 U.S. ATTR-CM patients in the first-line treatment setting, plus another 10,000 or ...

Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

(Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data showing that its whole-genome sequencing (WGS)-based platform for minimal residual disease (MRD) testing detected cancer ...